Orexo has a strong history of developing new products approved in markets all over the world. In order to ensure a continued inflow of new improved drugs, the development work at the R&D department in Uppsala, Sweden, has intensified. Filling an unmet need among healthcare professionals and patients is the key in the work of developing new innovative products for treatment of opioid addiction in all phases.
To read about each development project please go to the main menu Pipeline and its sub-menu.
1 Following a portfolio organization at Mundipharma Orexo will regain the ex-US rights as of April 13, 2019